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Accepted 12 September 2013AbstractDown syndrome is the most common autosomal chromosome aneuploidy. The prenatal Down syndrome screening protocol has been known
in Taiwan for the past 20 years. The maternal serum double markers required for the screening test was first implemented into the general
prenatal check-up back in 1994, where it had around a 60% detection rate at a 5% false positive rate. The first trimester combined test was started
in 2005, and the maternal serum quadruple test was introduced in 2008 to replace the previous double test. The overall detection rate for the
current screening strategies (first trimester combined or second trimester quadruple test) in Taiwan ranges between 80% and 85% at a fixed 5%
false positive rate. Noninvasive prenatal testing (NIPT) is the latest powerful fetal aneuploidy detection method and has become commercially
available in Taiwan starting from 2013. The sensitivity and specificity for NIPT are very high (both over 99%) according to large worldwide
studies. Our preliminary data for NIPT from 11 medical centers in Taiwan have also shown a 100% detection rate for Down syndrome and
Edwards syndrome, respectively. Invasive chromosome studies such as amniocentesis or chorionic villus sampling cannot be replaced by NIPT,
and all prenatal screening and NIPT results require confirmation using invasive testing. This review discusses the Down syndrome screening
method assessments and the progress of NIPT in Taiwan.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Down syndrome (DS) is the most common structural
chromosome abnormality, with an occurrence rate of around 1
in 800 [1,2]. The initial DS screening tool was used for
advanced maternal age patients (i.e., those over 35 years old)
in the early 1980s; however, only 30% of DS patients could be
detected by amniocentesis [3]. Second trimester maternal* Corresponding author. Department of Obstetrics and Gynecology, Chang
Gung Memorial Hospital at Linkou and Chang Gung University, College of
Medicine, 5, Fu-Shin Street, Taoyuan 333, Taiwan.
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http://dx.doi.org/10.1016/j.tjog.2013.10.003serum screening was introduced in the early 1990s using free
human beta chorionic gonadotropin (free b-hCG) and alpha-
fetoprotein (AFP) that significantly improved fetal aneu-
ploidy screening performance [4e6]. In Taiwan, we first
implemented the second trimester double test (free b-hCG and
AFP) in 1994 as part of the routine prenatal check-up for every
pregnant woman; this step was accompanied by a dramatic
decrease of DS live birth rates from 0.63 to 0.16 per 1000 live
births [7].
DS screening first started to shift to the first trimester
combined test worldwide from the late 1990s and early 2000s;
the combined test included the measurement of nuchal trans-
lucency thickness (NT), human chorionic gonadotropin (hCG)cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Summary of the detection rate for Down syndrome screening and noninvasive
prenatal testing in Taiwan versus literature findings (with around 5% false
positive rate).
Detection rate
(Taiwan), %
(n)
References Detection rate
(literature), %
(n)
References
Second
trimester
double test
56 (34/61) [5,6,8] 61 [4]
First trimester
combined test
87.5 (14/16) [27] 82e87 [11,12]
Second trimester
quadruple test
81.8 (9/11) [10] 81 [11,12]
Noninvasive
prenatal testing
100 (11/11) [18] 99.3 (590/594) [14,37e43]
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levels. The overall detection rate was higher than the second
trimester double test (85% vs. 60%) while maintaining the
same 5% false positive rate [4]. In Taiwan, we implemented
the first trimester combined test back in 2005 after some pi-
oneers obtained NT scanning licenses from the Fetal Medicine
Foundation (FMF) in London [8].
Recently in Taiwan, the maternal serum quadruple
screening test was started using two markers plus unconju-
gated estriol (uE3) and inhibin A from 2008 to replace the
insufficient detection power of the traditional double test [10].
The overall detection rate is 81% at a 5% false positive rate
[11,12]. The quadruple test for DS screening is mainly
applicable for general urban hospital populations, especially
for those individuals lacking qualified NT scanning doctors.
Currently, the first trimester combined test and second
trimester quadruple test are the main tools for routine prenatal
care in Taiwan [10].
NIPT has been a diagnostic tool for fetal chromosome
aneuploidies since Lo et al first found free fetal cell DNA in
the maternal plasma [13]. Chiu et al led this research and
launched a clinical service starting in 2011 [14e16]. The
overall DS detection specificity and sensitivity are both over
99%, as compared to 99.99% by invasive amniocentesis [17].
In Taiwan, NIPT is now commercially available, showing
100% DS detection compatible with other international studies
[18]. In this review, we summarize DS screening trends and
demonstrate the pilot data of NIPT screening in Taiwan.
Second trimester double test (1994)
The second trimester double test was the first DS screening
test; it was introduced to Taiwan approximately 20 years ago
[6]. It is generally offered between the 15th and 20th week of
gestation. It traditionally consists of some combination of
maternal serum marker analysis and maternal age. In the
1980s, researchers found that lower maternal serum AFP
levels in the second trimester were also associated with an
increased risk of DS [19,20].
Starting in 1994, the double test using free b-hCG and AFP
was introduced into routine prenatal examinations in Taiwan
[6]. The three largest studies carried out in Taiwan showed that
the double test detection rate ranged from 57% to 63%, with a
false positive rate of between 5.3% and 6.5% (Table 1)
[4e6,8,10e12,14,18,27,37e43]; these results are compatible
to those from Caucasian population studies [4e7]. Our un-
published data also revealed that the double test detection rate
among younger women was found to be only 45% with a false
positive rate of 3.0%; these results were comparable to the
46% detection rate from the study by Wald et al [4,8]. When
correlating the results of three major studies in Taiwan, the
average detection rate among women of young maternal age
(<34 years old) is 49% [8].
Routine screening always focuses on young mothers. In
Taiwan, over 90% of women with advanced age choose genetic
diagnostic testing [21]. Both the low cost of genetic diagnosis in
Taiwan and poor support systems for intellectually disabledchildren have resulted in Taiwanese women preferring amnio-
centesis rather than risk a DS baby, despite the fetal loss rate for
amniocentesis of nearly 1 in 300 [8].
Wald et al suggested that the maternal serum double test is
no longer justified as a routine screening tool for DS, on the
basis of relatively low detection rates and poor cost effec-
tiveness [22]. Since 2008 in Taiwan, the quadruple test with
higher detection ability has replaced most double testing after
implementation into routine prenatal care [10].
First trimester combined test (2005)
First trimester screening is normally conducted between the
11th and 14th week of gestation. NT is a powerful sonographic
marker for DS, and free b-hCG and PAPP-A are the
discriminatory serum factors [23,24]. These three markers are
used for calculating the likelihood ratio, and thus determine
individual risk of fetal DS [25]. The DS detection rate if
performing NT alone ranged from 64% to 70% with a 5% false
positive rate, depending on the study [11]. A combination of
NT measurement with the above two serum biochemical
markers (free b-hCG and PAPP-A) in the first trimester
comprises the “combined test” [25]. The detection rate for this
test is between 82% and 87% with a false positive rate of 5%;
this is even better than the second trimester quadruple test
[11]. Tsai et al published the first Taiwanese pilot data on the
first trimester combined test which showed nine out of 10 fetal
aneuploidies (including 2 DS) were diagnosed with a 4.7%
false positive rate [26]. Chou et al noted that the detection rate
for DS using the first trimester combined test was 87.5% (14
out of 16) with a false positive rate of 5.5% [27] (Table 1).
Cheng et al reported that the homocysteine level would affect
multiple of the median (MoM) of PAPP-A and adjustment of
DS risk should be considered [28]. In addition, Yang et al also
disclosed another soft marker (nasal bone length) during
second trimester using three-dimensional ultrasound that could
be applied for DS screening [29].
The first trimester combined test has the advantage of
obtaining results in the late first trimester. When indicated, this
allows karyotyping by chorionic villus sampling and early
surgical termination of pregnancy. In 2007, the American
College of Obstetrics and Gynecologists (ACOG) clinical
Table 2
The detection of Down syndrome results in eight noninvasive prenatal testing
studies, as compared with Taiwan data (modified from Benn et al [34]).
Trial [reference] Detection rate, % (n) False positive rate, % (n)
Chiu et al [14] 100 (86/86) 2.1 (3/146)
Ehrich et al [37] 100 (39/39) 0.24 (1/410)
Palomaki et al [38,43] 98.6 (209/212) 0.20 (3/1471)
Bianchi et al [39] 98.9 (89/90) 0.00 (0/410)
Sparks et al [41] 100 (36/36) 0.81 (1/123)
Ashoor et al [40] 100 (50/50) 0.00 (0/297)
Norton et al [42] 100 (81/81) 0.03 (1/2888)
Shaw et al [18] 100 (11/11) 0.00 (0/189)
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an effective screening test for DS for the general population
(level A evidence) [12]. The first trimester combined test was
introduced at major medical centers in Taiwan from the
beginning of 2005 following the FMF guidelines [8]. In 2013,
there are over 50 FMF certified sonographers in Taiwan. The
Department of Health in Taiwan also suggested that the first
trimester combined test should officially be incorporated into
routine care. One study showed that the first trimester com-
bined test was the most cost-effective screening tool [30].
Currently in Taiwan, the first trimester combined test acts
as the first-line DS screening in hospitals with certified doctors
or sonographers. The second trimester quadruple test acts as
the second-line screening tool when pregnant women are
either late for prenatal check-ups or in local clinics without
licensed doctors.
Second trimester quadruple test (2008)
One medical center in Taiwan studied uE3, in addition to
hCG and AFP as the third marker (triple test); they found an
overall DS detection rate of 78.6% [31]. Incorporating inhibin
A into the maternal serum DS screening in the second
trimester, along with AFP, hCG and uE3, was termed the
quadruple test, and was first used in 1996 [32]. The quadruple
test detection rate is approximately 83%, comparable with the
first trimester combined test [11].
According to the ACOG published guidelines, triple or
quadruple testing should be offered to pregnant women when
certified doctors are not available to perform a first trimester
combined test [12]. Starting in January 2008, the quadruple test
began to be provided to the general population in Taiwan [10].
The standard reference range for inhibin A has never been
determined among Asian women, therefore our pilot study to
determine normal values was performed to establish a database
[10]. Prior to performing maternal serum screening, informed
consent should be offered to every pregnant woman. Compre-
hensive genetic counseling could help patients in their decision
making after obtaining the results of DS screening [33].
Our data showed that 977 out of 21,481 women studied were
in the high-risk group (over 1 in 270). Most of these women
(86.2%) decided to have invasive procedures for genetic diag-
nosis. Nine cases of DS and 19 cases of other chromosomal
anomalies were detected prenatally. Two children with DS were
diagnosed post-delivery even though there was a low estimated
risk, which was determined following the quadruple test. The
detection rate was 81.8% (9 out of 11 cases), with a 4.4% false
positive rate. The respective median multiple values for AFP,
hCG, uE3 and inhibin A were 0.87, 2.34, 0.77 and 2.16 in the
affected cases [10]. Therefore, Taiwanese data on second
trimester quadruple testing showed compatible performances to
other international studies (Table 1).
Noninvasive prenatal testing (2013)
Just recently, NIPT analysis of cell-free DNA (cfDNA) in
maternal blood has been shown to be highly accurate in thedetection of fetal chromosomal aneuploidies, such as auto-
somal or sex chromosome-related disorders [34]. The fetal
DNA fraction is around 10e20% maternal plasma cfDNA and
can be detected from the 10th week of gestational age onward
[35]. There are several NIPT methods which include shotgun
sequencing, massively parallel sequencing (MPS), target MPS,
single nucleotide polymorphism-based approaches, methyl-
ated DNA-based approaches and digital PCR [34]. Currently,
the most common method is shotgun MPS [15,36], which is
based on the identification and counting of DNA fragment
numbers in maternal plasma samples. With next generation
sequencing, both fetal and maternal DNA fragments could be
simultaneously sequenced for millions of times. The differ-
ence of DNA count numbers in chromosome 21 will show up
in cases of DS, as compared to normal fetuses [15]. The
calculation formula varies according to the different study
groups. In general, the Z scores for each chromosome pair was
defined as increased dosage when Z > 3, and decreased
dosage when Z < 3 [15e17]. From the eight largest studies
in the literature, the overall DS detection rate was 99.3% (590/
594) with a 0.16% false positive rate [14,18,37e43] (Table 2).
Our pilot study was the first to demonstrate a prospective
cohort study in the Chinese population using NIPT for
detecting all fetal chromosomal aneuploidies [18]. It is also
the first study to compare NIPT results from extremely high-/
low-risk DS screening cases. There were 11 trisomy 21 cases,
eight trisomy 18 cases, three trisomy 13 cases, one trisomy 16
case, three 45 XO cases and one 47 XYY case detected pre-
natally (Table 3). There were no false positive cases in this
study. The detection rates for DS, trisomy 18, trisomy 13 and
other autosomal aneuploidies were 100%, compatible to other
international studies [14] (Tables 2 and 3). The false positive
rate was zero, indicative that NIPT is a powerful screening
tool. According to the latest ACOG guidelines, suggested
NIPT indications are advanced maternal age, abnormal ultra-
sound findings and a positive result from either the first or
second trimester screening [44]. The ACOG did not suggest
using NIPT as the first-line routine prenatal evaluation, as
NIPT is still more expensive as compared to other screening
tools; it also had poor medical cost effectiveness. Invasive
chromosome studies, such as amniocentesis, maintain a final
confirmatory role.
Pregnant women, who are often afraid of invasive amnio-
centesis, have already had early rupture of membranes, multiple
Table 3
Summary of aneuploidies detected by noninvasive prenatal testing in Taiwan
(modified from Shaw et al [18]).
Aneuploidies Sensitivity,
% (n)
Specificity,
% (n)
False
positive, %
False
negative, %
Trisomy 21 100 (11/11) 100 (189/189) 0 0
Trisomy 18 100 (8/8) 100 (192/192) 0 0
Trisomy 13 100 (3/3) 100 (197/197) 0 0
Trisomy 16 100 (1/1) 100 (199/199) 0 0
45, X 75 (3/4) 100 (196/196) 0 25
47, XYY 100 (1/1) 100 (199/199) 0 0
Overall 96 (27/28) 100 (172/172) 0 4
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tical indications for NIPT [44]. NIPT may be used to detect one
co-twin anomaly in twin pregnancies such as Turner syndrome
or Edwards syndrome [18]. More data are necessary to confi-
dentially apply such clinical testing in twin pregnancies. In the
near future, NIPT might be helpful as a noninvasive procedure
to assist with most parts of karyotyping.
NIPT currently remains limited in its ability to diagnose
mosaicism, microdeletion, microduplication, translocations
and triploidy [34]. Although one study claimed that NIPT
could detect mosaicism [39], we still need to explain the
application for all prospective clinicians who choose to
perform NIPT. In addition, NIPT cannot detect balanced
translocation as there is no DNA change in the entire fetal
genome. Hence, chromosome karyotyping remains the gold
standard for these patients. For other undetectable trisomies or
triploidies, obstetricians are not worried because the previ-
ously mentioned diseases are too severe to survive in the fetus
until birth; they are easy to find during prenatal ultrasound
examinations.
In summary, next generation sequencing for NIPT could be
efficiently applied in the general population for the detection
of both autosomal and sex chromosome-related aneuploidies
with very high sensitivity and specificity.
Conclusion
There has been 20 years of experience in Taiwan related to
prenatal screening, ranging from DS screening to noninvasive
prenatal testing. All clinical physicians have worked hard to
improve prenatal care, as shown by the dramatic decreases in
the DS live birth rate. We look forward to increased avail-
ability of high quality prenatal screening and diagnosis sys-
tems in Taiwan.
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